July 2017

New Product - Naglazyme

Naglazyme (galsulfase (rch)) is a normal variant form of the polymorphic human enzyme, N-acetylgalactosamine 4-sulfatase. Galsulfase (rch) is a lysosomal enzyme that catalyses the cleavage of the sulfate ester from terminal N-acetylgalactosamine 4-sulfate residues of glycosaminoglycans (GAG), chondroitin 4-sulfate and dermatan sulfate. GAG substrate accumulation throughout the body leads to widespread cellular, tissue and organ dysfunction. Naglazyme is indicated as long-term enzyme replacement therapy in Mucopolysaccharidosis VI (MPS VI, N-acetylgalactosamine 4-sulfatase deficiency, Maroteaux-Lamy syndrome). Naglazyme is supplied in vials containing 5 mg galsulfase (rch) per 5 mL solution in packs of 1.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au